We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . More info . X close

Molecular Infectious Disease Testing Market: Growth, Size, Share, and Trends

Report Code MD 9285
Published in Feb, 2025, By MarketsandMarkets™
Download PDF

Choose License Type

Buy Report Now Inquire Before Buying

Molecular Infectious Disease Testing Market by Product & Service (Kits, Instruments), Type (Singleplex, Multiplex), Test Type (Lab, PoC), Disease (STD, Flu, GI, HAI), Technology (PCR, NGS), End User (Diagnostic Labs, Hospitals) - Global Forecast to 2029

Overview

The global molecular infectious disease testing market, valued at US$8.49 billion in 2023, is forecasted to grow at a robust CAGR of 13.7%, reaching US$9.37 billion in 2024 and an impressive US$17.78 billion by 2029. Major drivers of market growth include rising burden of infectious diseases and rapid technological advancements in molecular diagnostics. The increased incidence of emerging infectious diseases and antibiotic-resistant infections leads to greater demand for accurate and reliable diagnostics. In addition, there are rapid advances in the efficiency of molecular testing techniques, such as PCR and next-generation sequencing, which have improved diagnostic capabilities. These provide results that are more sensitive and at a faster speed, and allow for the simultaneous identification of multiple pathogens, which becomes vital in handling complex and continually changing infectious disease threats. These are some of the major contributors to the growing market.

Molecular Infectious Disease Testing Market – Global Forecast and Key Opportunities to 2029

Attractive Opportunities in the Molecular Infectious Disease Testing Market

Asia Pacific

Market growth in the Asia Pacific can be attributed to the improving healthcare infrastructure, rising infectious disease prevalence, and economic growth in developing countries in the region.

The market is driven by the rising prevalence of infectious diseases globally and growing focus on R&D in molecular diagnostic testing.

Emerging markets are expected to offer lucrative growth opportunities for players in the molecular infectious disease testing market.

The Asia Pacific molecular infectious disease testing market is expected to be worth USD 3,843.5 million by 2029, growing at CAGR of 15.8% during the forecast period.

Product approvals and partnerships were the most widely adopted growth strategies by market players.

Global Molecular Infectious Disease Testing Market Dynamics

DRIVER: Rising financial support for molecular testing

Growing funding for molecular testing is an important growth factor for the molecular infectious disease testing market. Governments, healthcare organizations, and private investors are increasing financial support to advance diagnostic technologies and increase access to molecular testing. Such funding is also driving innovation in technologies such as real-time PCR and next-generation sequencing, which are becoming faster, more accurate, and cheaper. Public health efforts to control infectious disease outbreaks also lead to increasing investments in molecular testing infrastructure. The increased funding is also helping to integrate molecular testing into healthcare systems in low-resource settings, thereby improving global disease control efforts and patient outcomes.

RESTRAINT: Uneven reimbursement policies

Inconsistent reimbursement policies are a major restraint in the molecular infectious disease testing market. Differences in reimbursement rates and criteria between regions and healthcare systems can pose challenges for both providers and patients. Such inconsistencies may delay adoption, limit access to needed diagnostic tests, and increase the financial burden on healthcare providers. The lack of uniformity in policies for reimbursement might also discourage laboratories and healthcare facilities from investing in high-end molecular testing platforms, making them less accessible in routine clinical practice. This inconsistency regarding access and affordability might hamper the widespread use of molecular infectious testing.

 

OPPORTUNITY: Increasing opportunities for growth in developing countries

High growth opportunities in emerging economies are one of the major opportunities for the molecular infectious disease testing market. With the improvement in healthcare infrastructure, rising disposable incomes, and increased awareness of infectious diseases, demand for advanced diagnostic solutions is increasing at a rapid pace in these regions. Government policies and international alliances to promote healthcare investments further favour the use of molecular diagnostics for infectious disease testing. The increasing healthcare market in regions such as Asia, Latin America, and Africa provides a lucrative opportunity for the market players to provide innovative testing solutions, hence propelling the growth of the molecular infectious disease testing market in these regions.

CHALLENGES: Operational challenges and workforce shortages

Key challenges in the molecular infectious disease testing market include operational barriers and labor shortages. Lack of access to skilled personnel is a constraint, especially in emerging markets. It may affect the adoption and efficient use of advanced molecular diagnostic technologies. The operational issues that include infrastructural inadequacies, delayed regulatory approvals, and supply chain breakdowns are the other factors which would delay the adoption of molecular infectious disease testing solutions. These factors may impact the integration rate of molecular testing into health systems and also put a strain on resources, making it difficult for healthcare providers to keep up with growing demand.

Global Molecular Infectious Disease Testing Market Ecosystem Analysis

The molecular infectious disease testing market thrives on a complex ecosystem. It consists of product types, such as PCR-based tests and sequencing technologies, that are used in diagnostic laboratories, hospitals, and clinics. The manufacturers focus on the design and optimization of the products. Distributors include third-party vendors as well as e-commerce platforms. The key stakeholders include the population of patients being diagnosed, the investors, and the regulatory bodies.

Molecular Infectious Disease Testing Market Ecosystem
 

The reagents & kits segment accounted for the largest share of the market in 2023, by product

The molecular infectious disease testing market can be segmented based on product & service into reagents & kits, instruments, and services & software. Reagents and kits represented the largest products and services-based segment in the molecular infectious disease testing market as they play a crucial role in accurate and efficient diagnosis. These include primers, probes, enzymes, and diagnostic kits that are needed for the molecular tests. This segment is driven by large patient volumes associated with infectious disease diagnoses, as well as the recurring need for reagents & kits in regular testing. Since the demand for molecular tests continues to increase due to rising prevalence of infections and adoption of modern diagnostic technologies, the recurring purchase of reagents and kits on a steady basis contributes to its market dominance.

The sexually transmitted disease segment dominated the molecular infectious disease testing market in 2023, based on disease

Based on disease, the molecular infectious disease testing market has been divided into the global molecular infectious disease testing market is segmented into respiratory infectious diseases, gastrointestinal infectious diseases, sexually transmitted diseases, vaginitis, meningitis, vector-borne diseases, hospital-acquired infections, and other infectious diseases. The largest share of the molecular infectious disease testing market in 2023 was held by the sexually transmitted diseases segment. This was largely due to the rising prevalence of sexually transmitted diseases, coupled with growing awareness and efforts for early detection. Molecular technologies like PCR and nucleic acid amplification tests can give accurate, sensitive, and fast results, which is very important for the diagnosis and treatment of these infections. Moreover, public health initiatives for screening, prevention, and treatment improvement, coupled with the increased adoption of molecular diagnostics in clinics and hospitals, is driving the growth of this segment globally.

In 2023, North America Held the Largest Share of the Molecular Infectious Disease Testing Market.

The market for molecular infectious disease testing has been segmented into six major geographical regions: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, and the GCC countries. North America remained the largest regional market for molecular infectious disease testing in 2023. Advanced healthcare infrastructure, increased accessibility to technologically advanced diagnostic solutions, and high investments in research and development position it to dominate the market. The presence of dominant market players in this region, coupled with government support and public health initiatives, strengthens the growth perspective. High burden of infectious diseases as well as growing demand for accurate and timely testing solutions have fueled the uptake of molecular infectious disease tests in the region.

HIGHEST CAGR MARKET IN 2023
US FASTEST GROWING MARKET IN THE REGION
Molecular Infectious Disease Testing Market Region

Recent Developments of Molecular Infectious Disease Testing Market

  • In December 2024, bioMérieux (France) announced that its BIOFIRE FILMARRAY Tropical Fever (TF) Panel has received US Food and Drug Administration (FDA) Special 510(k) clearance. This innovative polymerase-chain reaction (PCR) testing solution offers fast and accurate pathogen identification in patients with unexplained fever, helping to optimize treatment overall.
  • In November 2024, QIAGEN (Netherlands) announced that the US FDA has cleared the QIAstat-Dx Meningitis/Encephalitis Panel for clinical use.
  • In September 2024, F. Hoffmann-La Roche Ltd (Switzerland) launched the cobas Respiratory flex test, the first test that uses Roche’s novel and proprietary TAGS (Temperature-Activated Generation of Signal) technology. This technology uses multiplex polymerase chain reaction (PCR) testing, combined with color, temperature, and data processing, to identify as many as 15 pathogens in a single PCR test.
  • In April 2024, DiaSorin S.p.A (Italy) received FDA 510(k) clearance for its NxTAG Respiratory Pathogen Panel (RPP) v2, an enhanced version of the panel in its growing molecular multiplexing portfolio. The updated panel improves test usability and was developed in collaboration with the Biomedical Advanced Research and Development Authority (BARDA), part of the US Department of Health and Human Services, to support the clearance of this updated syndromic test.

Key Market Players

Want to explore hidden markets that can drive new revenue in Molecular Infectious Disease Testing Market?

Scope of the Report

Report Metric Details
Market size available for years 2022-2029
Base Year Considered 2023
Forecast period 2024-2029
Forecast units Value (USD) and Volume (Thousands)
Segments covered Product & Service, Type, Test Type, Disease, Technology, and End User
Geographies covered North America, Europe, Asia Pacific, Latin America, Middle East & Africa, and the GCC Countries

 

Key Questions Addressed by the Report

What are the recent trends affecting the molecular infectious disease testing market?
The recent trends to affect the molecular infectious disease testing market includes diagnostic laboratories adopting high-throughput testing platforms to continue to meet increasing demand for timely diagnostics. Multiplex assays that allow clinicians to test for multiple pathogens in one test are driving efficiency and accuracy in clinical practice. Advances in molecular technologies, including the next-generation sequencing (NGS), are facilitating more sensitive detection and surveillance of pathogens. Strategic collaborations of diagnostic companies expanding product offerings or improving test access also shape the market landscape.
What are the types of molecular infectious disease tests?
Based on type, the molecular infectious disease testing market can broadly be divided into singleplex testing and multiplex testing. Multiplex testing captured the largest portion of the molecular infectious disease testing market because of its ability to identify multiple pathogens through a single test. This results in saving time by not having to conduct multiple tests, which may be costly in the long term for healthcare providers. Its high accuracy in delivering comprehensive results has made it a much-preferred solution in diagnostic laboratories as well as hospitals & clinics. The steady rise in prevalence of infectious diseases further propels the use of multiplexing, which solidifies its dominant position in the market.
Who are the key players in the molecular infectious disease testing market?
The key players in this market are Danaher (US), F. Hoffmann-La Roche Ltd (Switzerland), bioMérieux (France), Hologic, Inc. (US), Abbott (US), Thermo Fisher Scientific Inc. (US), QIAGEN (Netherands), Revvity (US), Siemens Healthineers AG (Germany), BD (US), Grifols, S.A. (Spain), QuidelOrtho Corporation (US), DiaSorin S.p.A. (Italy), Bruker (US), Seegene Inc. (South Korea), Genetic Signatures (Australia), Co-Diagnostics, Inc. (US), Savyon Diagnostics (Israel), Vela Diagnostics (Singapore), Molbio Diagnostics Pvt. Ltd. (India), Uniogen OY (Finland), geneOmbio Technologies (India), Advanced Molecular Diagnostics (UK), GeneFirst Limited (UK), and altona Diagnostics GmbH (Germany).
Who are the major end users of molecular infectious disease tests?
The molecular infectious disease testing market is bifurcated into diagnostic laboratories, hospitals & clinics, and other end users, based on end user. Diagnostic laboratories accounted for the largest share in the market of molecular infectious disease testing. They possess advanced infrastructural and technological set-up to process a large number of molecular tests with proper accuracy and conduct molecular diagnostics tests involving PCR and sequencing technologies. Increasing demand for accurate and timely infectious disease diagnosis, along with ability to handle large-scale tests during outbreaks, has positioned diagnostic laboratories are the largest end user segment.
Which region is lucrative for the molecular infectious disease testing market?
One of the most promising markets for molecular infectious disease testing is the Asia Pacific region, due to rapidly expanding healthcare infrastructure and increasing healthcare expenditure of this region along with the growing awareness of the importance of early diagnosis of infectious diseases. In addition, growing medical tourism in countries like India, Thailand, and Malaysia is further fuelling the demand for advanced molecular diagnostics, thus making the market even more potential in this region.

 

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the Molecular Infectious Disease Testing Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request

Table of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
INTRODUCTION
38
RESEARCH METHODOLOGY
42
EXECUTIVE SUMMARY
56
PREMIUM INSIGHTS
62
MARKET OVERVIEW
66
  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    DRIVERS
    - Rising burden of infectious diseases
    - Rapid technological advancements in molecular diagnostics
    - Growing funding for molecular testing
    RESTRAINTS
    - Inconsistent reimbursement policies
    OPPORTUNITIES
    - High growth opportunities in emerging economies
    CHALLENGES
    - Changing regulatory landscape
    - Operational barriers and labor shortage issues
  • 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • 5.4 PRICING ANALYSIS
    INDICATIVE SELLING PRICE TREND, BY PRODUCT
    INDICATIVE SELLING PRICE TREND OF SEXUALLY TRANSMITTED DISEASE TESTS, BY KEY PLAYER
    INDICATIVE SELLING PRICE TREND OF GASTROINTESTINAL DISEASE TESTS, BY KEY PLAYER
    INDICATIVE SELLING PRICE TREND, BY REGION
  • 5.5 VALUE CHAIN ANALYSIS
  • 5.6 SUPPLY CHAIN ANALYSIS
  • 5.7 ECOSYSTEM ANALYSIS
  • 5.8 INVESTMENT AND FUNDING SCENARIO
  • 5.9 TECHNOLOGY ANALYSIS
    KEY TECHNOLOGIES
    - Polymerase chain reaction
    COMPLEMENTARY TECHNOLOGIES
    - Isolated nucleic acid amplification technology
    ADJACENT TECHNOLOGIES
    - Next-generation sequencing
  • 5.10 PATENT ANALYSIS
  • 5.11 TRADE ANALYSIS
    IMPORT DATA FOR HS CODE 3822
    EXPORT DATA FOR HS CODE 3822
  • 5.12 KEY CONFERENCES AND EVENTS, 2025–2026
  • 5.13 CASE STUDY ANALYSIS
    CASE STUDY 1: IMPROVED PATHOGEN-DIRECTED TREATMENT THROUGH RAPID SYNDROMIC PCR TESTING
    CASE STUDY 2: CLINICAL IMPACT OF MULTIPLEX MOLECULAR DIAGNOSTIC TESTING IN CHILDREN WITH ACUTE GASTROENTERITIS
    CASE STUDY 3: IMPACT OF MOLECULAR POINT OF CARE TESTING FOR GROUP A STREPTOCOCCUS PHARYNGITIS
  • 5.14 REGULATORY LANDSCAPE
    REGULATORY ANALYSIS
    - NORTH AMERICA
    - EUROPE
    - ASIA PACIFIC
    - LATIN AMERICA
    - MIDDLE EAST
    REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.15 PORTER’S FIVE FORCES ANALYSIS
    BARGAINING POWER OF SUPPLIERS
    BARGAINING POWER OF BUYERS
    THREAT OF NEW ENTRANTS
    THREAT OF SUBSTITUTES
    INTENSITY OF COMPETITIVE RIVALRY
  • 5.16 KEY STAKEHOLDERS AND BUYING CRITERIA
    KEY STAKEHOLDERS IN BUYING PROCESS
    BUYING CRITERIA
  • 5.17 IMPACT OF AI ON MOLECULAR INFECTIOUS DISEASE TESTING MARKET
    INTRODUCTION
    MARKET POTENTIAL OF AI IN MOLECULAR INFECTIOUS DISEASE TESTING APPLICATIONS
    AI USE CASES
    KEY COMPANIES IMPLEMENTING AI
    FUTURE OF AI IN MOLECULAR INFECTIOUS DISEASE TESTING MARKET
MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE
103
  • 6.1 INTRODUCTION
  • 6.2 REAGENTS & KITS
    ONGOING INNOVATIONS IN MOLECULAR DIAGNOSTICS TO SPUR GROWTH
  • 6.3 INSTRUMENTS
    RISING PREVALENCE OF INFECTIOUS DISEASES TO FOSTER GROWTH
  • 6.4 SERVICES & SOFTWARE
    INCREASING UPTAKE OF ADVANCED INSTRUMENTS TO FACILITATE GROWTH
MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE
116
  • 7.1 INTRODUCTION
  • 7.2 MULTIPLEX TESTING
    RISING DEMAND FOR FASTER DIAGNOSIS TO PROMOTE GROWTH
  • 7.3 SINGLEPLEX TESTING
    NEED FOR AFFORDABLE AND USER-FRIENDLY TESTING TO AUGMENT GROWTH
MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE
125
  • 8.1 INTRODUCTION
  • 8.2 LABORATORY TESTS
    INCREASING NEED FOR AUTOMATION TO FAVOR GROWTH
  • 8.3 POINT OF CARE TESTS
    GROWING AWARENESS ABOUT DISEASE SURVEILLANCE, SCREENING, AND OUTBREAK RESPONSE TO DRIVE MARKET
MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE
134
  • 9.1 INTRODUCTION
  • 9.2 RESPIRATORY INFECTIOUS DISEASES
    INFLUENZA
    - Growing focus on faster diagnosis and control to propel market
    TUBERCULOSIS
    - Rise in undiagnosed and untreated cases to promote growth
    PHARYNGITIS
    - Need to differentiate between bacterial and viral infections to fuel growth
    OTHER RESPIRATORY INFECTIOUS DISEASES
  • 9.3 GASTROINTESTINAL INFECTIOUS DISEASES
    HEPATITIS
    - Rising government initiatives to expedite growth
    OTHER GASTROINTESTINAL INFECTIOUS DISEASES
  • 9.4 SEXUALLY TRANSMITTED DISEASES
    HUMAN IMMUNODEFICIENCY VIRUS
    - Increasing number of blood transfusions and blood donations to augment growth
    HUMAN PAPILLOMAVIRUS
    - Technological advancements for preventing human papillomavirus infections to drive market
    CHLAMYDIA TRACHOMATIS
    - Increasing development of molecular tests to aid growth
    NEISSERIA GONORRHOEAE
    - Increasing development of novel assays to boost market
    SYPHILIS
    - Growing demand for affordable and rapid molecular diagnostic solutions to drive market
    OTHER SEXUALLY TRANSMITTED DISEASES
  • 9.5 HOSPITAL-ACQUIRED INFECTIONS
    GROWING BURDEN OF METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS TO FUEL MARKET
  • 9.6 VAGINITIS
    INCREASING AWARENESS ABOUT WOMEN’S HEALTH TO BOLSTER GROWTH
  • 9.7 MENINGITIS
    RISING INCIDENCE OF INVASIVE MENINGOCOCCAL DISEASE TO ASSIST GROWTH
  • 9.8 VECTOR-BORNE DISEASES
    GROWING FOCUS ON DISEASE SURVEILLANCE TO PROPEL MARKET
  • 9.9 OTHER INFECTIOUS DISEASES
MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY
195
  • 10.1 INTRODUCTION
  • 10.2 POLYMERASE CHAIN REACTION
    NEED FOR HIGH PRECISION FOR DISEASE IDENTIFICATION TO SUPPORT GROWTH
  • 10.3 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY
    EMERGENCE OF NEW PATHOGENS TO STIMULATE GROWTH
  • 10.4 DNA SEQUENCING & NEXT-GENERATION SEQUENCING
    GROWING APPLICATIONS IN DIAGNOSING BACTERIAL, VIRAL, FUNGAL, AND PARASITIC INFECTIONS TO DRIVE MARKET
  • 10.5 IN SITU HYBRIDIZATION
    NEED FOR SAFER AND MORE PRACTICAL TESTING IN CLINICAL SETTINGS TO FUEL MARKET
  • 10.6 DNA MICROARRAYS
    NEED FOR AFFORDABLE AND SENSITIVE DETECTION TO ENCOURAGE GROWTH
  • 10.7 OTHER TECHNOLOGIES
MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER
215
  • 11.1 INTRODUCTION
  • 11.2 DIAGNOSTIC LABORATORIES
    GROWING EMPHASIS ON QUALITY CONTROL AND STANDARDIZED TESTING PROTOCOLS TO BOOST MARKET
  • 11.3 HOSPITALS & CLINICS
    RISING PATIENT VOLUME TO CONTRIBUTE TO GROWTH
  • 11.4 OTHER END USERS
MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY REGION
225
  • 12.1 INTRODUCTION
  • 12.2 NORTH AMERICA
    MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    US
    - Presence of advanced healthcare infrastructure to augment growth
    CANADA
    - Favorable government initiatives to fuel market
  • 12.3 EUROPE
    MACROECONOMIC OUTLOOK FOR EUROPE
    GERMANY
    - Increasing healthcare expenditure to advance growth
    UK
    - Growing number of diagnostic centers to fuel market
    FRANCE
    - Increasing demand for early disease diagnosis to augment growth
    ITALY
    - Growing adoption of advanced diagnostic technologies to fuel market
    RUSSIA
    - Increasing access to quality healthcare to facilitate growth
    SPAIN
    - Growing public health initiatives to boost market
    REST OF EUROPE
  • 12.4 ASIA PACIFIC
    MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    CHINA
    - Rising public access to modern healthcare to spur growth
    JAPAN
    - Universal healthcare reimbursement policy to foster growth
    INDIA
    - Increased private and public investments to bolster growth
    AUSTRALIA
    - Growing investments for testing centers and treatment facilities to drive market
    REST OF ASIA PACIFIC
  • 12.5 LATIN AMERICA
    MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    BRAZIL
    - Growing focus on improving healthcare infrastructure to fuel market
    MEXICO
    - Increasing accessibility and affordability of healthcare services to foster growth
    REST OF LATIN AMERICA
  • 12.6 MIDDLE EAST & AFRICA
    BOOMING HEALTHCARE INVESTMENTS TO AID GROWTH
    MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 12.7 GCC COUNTRIES
    GROWING PUBLIC HEALTHCARE FUNDING TO DRIVE MARKET
    MACROECONOMIC OUTLOOK FOR GCC COUNTRIES
COMPETITIVE LANDSCAPE
342
  • 13.1 INTRODUCTION
  • 13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN MOLECULAR INFECTIOUS DISEASE TESTING MARKET
  • 13.3 REVENUE ANALYSIS, 2021–2023
  • 13.4 MARKET SHARE ANALYSIS, 2023
  • 13.5 MARKET SHARE ANALYSIS OF EMEA REGION, 2023
  • 13.6 COMPANY VALUATION AND FINANCIAL METRICS
  • 13.7 BRAND/PRODUCT COMPARISON
  • 13.8 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
    STARS
    EMERGING LEADERS
    PERVASIVE PLAYERS
    PARTICIPANTS
    COMPANY FOOTPRINT, KEY PLAYERS, 2023
    - Company footprint
    - Region footprint
    - Product & service footprint
    - Test type footprint
    - Disease footprint
  • 13.9 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
    PROGRESSIVE COMPANIES
    RESPONSIVE COMPANIES
    DYNAMIC COMPANIES
    STARTING BLOCKS
    COMPETITIVE BENCHMARKING OF STARTUPS/SMES, 2023
    - Detailed list of key startups/SMEs
    - Competitive benchmarking of startups/SMEs
  • 13.10 COMPETITIVE SCENARIO
    PRODUCT LAUNCHES AND APPROVALS
    DEALS
COMPANY PROFILES
362
  • 14.1 KEY PLAYERS
    DANAHER
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    F. HOFFMANN-LA ROCHE LTD
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    BIOMÉRIEUX
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    HOLOGIC, INC.
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    ABBOTT
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    THERMO FISHER SCIENTIFIC INC.
    - Business overview
    - Products offered
    - Recent developments
    QIAGEN
    - Business overview
    - Products offered
    - Recent developments
    REVVITY
    - Business overview
    - Products offered
    GRIFOLS, S.A.
    - Business overview
    - Products offered
    - Recent developments
    SEEGENE INC.
    - Business overview
    - Products offered
    - Recent developments
    DIASORIN S.P.A.
    - Business overview
    - Products offered
    - Recent developments
    SIEMENS HEALTHINEERS AG
    - Business overview
    - Products offered
    - Recent developments
    BD
    - Business overview
    - Products offered
    - Recent developments
  • 14.2 OTHER PLAYERS
    QUIDELORTHO CORPORATION
    BRUKER
    GENETIC SIGNATURES
    CO-DIAGNOSTICS, INC.
    VELA DIAGNOSTICS
    MOLBIO DIAGNOSTICS PVT. LTD.
    SAVYON DIAGNOSTICS
    UNIOGEN OY
    GENEOMBIO TECHNOLOGIES
    ADVANCED MOLECULAR DIAGNOSTICS
    ALTONA DIAGNOSTICS GMBH
    GENEFIRST LIMITED
APPENDIX
440
  • 15.1 DISCUSSION GUIDE
  • 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
  • 15.3 CUSTOMIZATION OPTIONS
  • 15.4 RELATED REPORTS
  • 15.5 AUTHOR DETAILS
LIST OF TABLES
 
  • TABLE 1 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: INCLUSIONS AND EXCLUSIONS
  • TABLE 2 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: KEY DATA FROM PRIMARY SOURCES
  • TABLE 3 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: RISK ANALYSIS
  • TABLE 4 GLOBAL HIV DATA, 2020 VS. 2022 VS. 2023
  • TABLE 5 INDICATIVE SELLING PRICE TREND OF MOLECULAR INFECTIOUS DISEASE TESTING PRODUCTS, 2022–2024
  • TABLE 6 INDICATIVE SELLING PRICE TREND OF SEXUALLY TRANSMITTED DISEASE TESTS, BY KEY PLAYER, 2022–2024
  • TABLE 7 INDICATIVE SELLING PRICE TREND OF GASTROINTESTINAL INFECTIOUS DISEASE TESTS, BY KEY PLAYER, 2022–2024
  • TABLE 8 INDICATIVE SELLING PRICE TREND OF MOLECULAR INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2022–2024
  • TABLE 9 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: ROLE OF COMPANIES IN ECOSYSTEM
  • TABLE 10 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: INNOVATIONS AND PATENT REGISTRATIONS, 2022–2023
  • TABLE 11 IMPORT DATA FOR HS CODE 3822 (DIAGNOSTIC AND LABORATORY REAGENTS), BY COUNTRY, 2019–2023 (USD MILLION)
  • TABLE 12 EXPORT DATA FOR HS CODE 3822 (DIAGNOSTIC AND LABORATORY REAGENTS), BY COUNTRY, 2019–2023 (USD MILLION)
  • TABLE 13 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: KEY CONFERENCES AND EVENTS, 2025–2026
  • TABLE 14 CLASSIFICATION OF IVD DEVICES IN EUROPE
  • TABLE 15 TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS IN JAPAN
  • TABLE 16 CLASSIFICATION OF IVD MEDICAL DEVICES IN AUSTRALIA
  • TABLE 17 NORTH AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 18 EUROPE: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 19 ASIA PACIFIC: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 20 LATIN AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 21 REST OF THE WORLD: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 22 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: PORTER’S FIVE FORCES ANALYSIS
  • TABLE 23 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE (%)
  • TABLE 24 KEY BUYING CRITERIA, BY PRODUCT & SERVICE
  • TABLE 25 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 26 KEY REAGENTS & KITS AVAILABLE IN MARKET
  • TABLE 27 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR REAGENTS & KITS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 28 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR REAGENTS & KITS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 29 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR REAGENTS & KITS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 30 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR REAGENTS & KITS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 31 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR REAGENTS & KITS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 32 KEY TESTING INSTRUMENTS AVAILABLE IN MARKET
  • TABLE 33 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR INSTRUMENTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 34 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR INSTRUMENTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 35 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR INSTRUMENTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 36 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR INSTRUMENTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 37 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR INSTRUMENTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 38 KEY SOFTWARE SOLUTIONS AVAILABLE IN MARKET
  • TABLE 39 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SERVICES & SOFTWARE, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 40 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SERVICES & SOFTWARE, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 41 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SERVICES & SOFTWARE, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 42 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SERVICES & SOFTWARE, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 43 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SERVICES & SOFTWARE, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 44 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 45 KEY MULTIPLEX TESTING PRODUCTS AVAILABLE IN MARKET
  • TABLE 46 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR MULTIPLEX TESTING, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 47 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR MULTIPLEX TESTING, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 48 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR MULTIPLEX TESTING, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 49 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR MULTIPLEX TESTING, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 50 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR MULTIPLEX TESTING, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 51 KEY SINGLEPLEX TESTING PRODUCTS AVAILABLE IN MARKET
  • TABLE 52 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SINGLEPLEX TESTING, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 53 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SINGLEPLEX TESTING, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 54 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SINGLEPLEX TESTING, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 55 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SINGLEPLEX TESTING, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 56 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SINGLEPLEX TESTING, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 57 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • TABLE 58 KEY LABORATORY-BASED TESTS AND DEVICES AVAILABLE IN MARKET
  • TABLE 59 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR LABORATORY TESTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 60 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR LABORATORY TESTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 61 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR LABORATORY TESTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 62 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR LABORATORY TESTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 63 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR LABORATORY TESTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 64 KEY POINT OF CARE TESTS AND DEVICES AVAILABLE IN MARKET
  • TABLE 65 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR POINT OF CARE TESTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 66 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR POINT OF CARE TESTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 67 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR POINT OF CARE TESTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 68 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR POINT OF CARE TESTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 69 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR POINT OF CARE TESTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 70 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2022–2029 (USD MILLION)
  • TABLE 71 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 72 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 73 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 74 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 75 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 76 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 77 KEY INFLUENZA TESTING PRODUCTS AVAILABLE IN MARKET
  • TABLE 78 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR INFLUENZA, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 79 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR INFLUENZA, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 80 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR INFLUENZA, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 81 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR INFLUENZA, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 82 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR INFLUENZA, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 83 KEY TUBERCULOSIS TESTING PRODUCTS AVAILABLE IN MARKET
  • TABLE 84 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR TUBERCULOSIS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 85 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR TUBERCULOSIS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 86 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR TUBERCULOSIS, BY COUNTRY, 2022–2029 (IN THOUSANDS)
  • TABLE 87 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR TUBERCULOSIS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 88 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR TUBERCULOSIS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 89 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR TUBERCULOSIS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 90 KEY PHARYNGITIS TESTING PRODUCTS AVAILABLE IN MARKET
  • TABLE 91 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR PHARYNGITIS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 92 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR PHARYNGITIS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 93 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR PHARYNGITIS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 94 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR PHARYNGITIS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 95 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR PHARYNGITIS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 96 OTHER KEY RESPIRATORY INFECTION DISEASE TESTING PRODUCTS AVAILABLE IN MARKET
  • TABLE 97 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER RESPIRATORY INFECTIOUS DISEASES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 98 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 99 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 100 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 101 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 102 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 103 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 104 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 105 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 106 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 107 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 108 KEY HEPATITIS TESTING PRODUCTS AVAILABLE IN MARKET
  • TABLE 109 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HEPATITIS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 110 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HEPATITIS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 111 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HEPATITIS, BY COUNTRY, 2022–2029 (IN THOUSANDS)
  • TABLE 112 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HEPATITIS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 113 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HEPATITIS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 114 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HEPATITIS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 115 OTHER KEY GASTROINTESTINAL INFECTIOUS DISEASE TESTING PRODUCTS AVAILABLE IN MARKET
  • TABLE 116 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER GASTROINTESTINAL INFECTIOUS DISEASES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 117 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER GASTROINTESTINAL INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 118 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER GASTROINTESTINAL INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 119 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER GASTROINTESTINAL INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 120 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER GASTROINTESTINAL INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 121 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 122 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 123 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 124 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 125 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 126 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 127 KEY HIV TESTING PRODUCTS AVAILABLE IN MARKET
  • TABLE 128 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HIV, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 129 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HIV, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 130 NORTH AMERICA: MOLECULAR INFECTIOUS TESTING MARKET FOR HIV, BY COUNTRY, 2022–2029 (IN THOUSANDS)
  • TABLE 131 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HIV, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 132 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HIV, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 133 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HIV, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 134 KEY HUMAN PAPILLOMAVIRUS TESTING PRODUCTS AVAILABLE IN MARKET
  • TABLE 135 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HUMAN PAPILLOMAVIRUS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 136 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HUMAN PAPILLOMAVIRUS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 137 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HUMAN PAPILLOMAVIRUS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 138 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HUMAN PAPILLOMAVIRUS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 139 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HUMAN PAPILLOMAVIRUS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 140 KEY CHLAMYDIA TRACHOMATIS TESTING PRODUCTS AVAILABLE IN MARKET
  • TABLE 141 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR CHLAMYDIA TRACHOMATIS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 142 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR CHLAMYDIA TRACHOMATIS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 143 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR CHLAMYDIA TRACHOMATIS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 144 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR CHLAMYDIA TRACHOMATIS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 145 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR CHLAMYDIA TRACHOMATIS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 146 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR NEISSERIA GONORRHOEAE, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 147 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR NEISSERIA GONORRHOEAE, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 148 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR NEISSERIA GONORRHOEAE, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 149 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR NEISSERIA GONORRHOEAE, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 150 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR NEISSERIA GONORRHOEAE, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 151 KEY SYPHILIS TESTING PRODUCTS AVAILABLE IN MARKET
  • TABLE 152 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SYPHILIS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 153 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SYPHILIS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 154 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SYPHILIS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 155 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SYPHILIS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 156 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SYPHILIS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 157 OTHER KEY SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS AVAILABLE IN MARKET
  • TABLE 158 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER SEXUALLY TRANSMITTED DISEASES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 159 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 160 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 161 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 162 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 163 KEY HOSPITAL-ACQUIRED INFECTION TESTING PRODUCTS AVAILABLE IN MARKET
  • TABLE 164 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 165 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 166 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 167 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 168 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 169 KEY VAGINITIS TESTING PRODUCTS AVAILABLE IN MARKET
  • TABLE 170 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR VAGINITIS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 171 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR VAGINITIS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 172 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR VAGINITIS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 173 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR VAGINITIS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 174 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR VAGINITIS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 175 KEY MENINGITIS TESTING PRODUCTS AVAILABLE IN MARKET
  • TABLE 176 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR MENINGITIS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 177 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR MENINGITIS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 178 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR MENINGITIS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 179 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR MENINGITIS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 180 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR MENINGITIS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 181 KEY VECTOR-BORNE DISEASE TESTING PRODUCTS AVAILABLE IN MARKET
  • TABLE 182 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR VECTOR-BORNE DISEASES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 183 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR VECTOR-BORNE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 184 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR VECTOR-BORNE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 185 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR VECTOR-BORNE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 186 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR VECTOR-BORNE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 187 OTHER KEY INFECTIOUS DISEASE TESTING PRODUCTS AVAILABLE IN MARKET
  • TABLE 188 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER INFECTIOUS DISEASES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 189 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 190 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 191 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 192 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 193 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 194 KEY POLYMERASE CHAIN REACTION-BASED TESTS AND DEVICES AVAILABLE IN MARKET
  • TABLE 195 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 196 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 197 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 198 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 199 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 200 KEY ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY-BASED TESTS AND DEVICES AVAILABLE IN MARKET
  • TABLE 201 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 202 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 203 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 204 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 205 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 206 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 207 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 208 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 209 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 210 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 211 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR IN SITU HYBRIDIZATION, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 212 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 213 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 214 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 215 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 216 KEY MICROARRAY-BASED PRODUCTS AVAILABLE IN MARKET
  • TABLE 217 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DNA MICROARRAYS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 218 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 219 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 220 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 221 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 222 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 223 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 224 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 225 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 226 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 227 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 228 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 229 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 230 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 231 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 232 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 233 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HOSPITALS & CLINICS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 234 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 235 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 236 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 237 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 238 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER END USERS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 239 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 240 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 241 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 242 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 243 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 244 MACROECONOMIC INDICATORS FOR NORTH AMERICA
  • TABLE 245 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 246 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 247 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 248 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • TABLE 249 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2022–2029 (USD MILLION)
  • TABLE 250 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 251 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 252 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 253 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 254 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 255 US: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 256 US: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 257 US: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • TABLE 258 US: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2022–2029 (USD MILLION)
  • TABLE 259 US: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 260 US: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 261 US: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 262 US: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 263 US: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 264 CANADA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 265 CANADA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 266 CANADA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • TABLE 267 CANADA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2022–2029 (USD MILLION)
  • TABLE 268 CANADA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 269 CANADA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 270 CANADA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 271 CANADA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 272 CANADA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 273 MACROECONOMIC INDICATORS FOR EUROPE
  • TABLE 274 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 275 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 276 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 277 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • TABLE 278 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2022–2029 (USD MILLION)
  • TABLE 279 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 280 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 281 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 282 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 283 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 284 GERMANY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 285 GERMANY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 286 GERMANY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • TABLE 287 GERMANY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2022–2029 (USD MILLION)
  • TABLE 288 GERMANY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 289 GERMANY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 290 GERMANY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 291 GERMANY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 292 GERMANY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 293 UK: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 294 UK: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 295 UK: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • TABLE 296 UK: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2022–2029 (USD MILLION)
  • TABLE 297 UK: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 298 UK: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 299 UK: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 300 UK: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 301 UK: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 302 FRANCE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 303 FRANCE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 304 FRANCE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • TABLE 305 FRANCE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2022–2029 (USD MILLION)
  • TABLE 306 FRANCE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 307 FRANCE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 308 FRANCE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 309 FRANCE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 310 FRANCE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 311 ITALY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 312 ITALY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 313 ITALY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • TABLE 314 ITALY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2022–2029 (USD MILLION)
  • TABLE 315 ITALY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 316 ITALY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 317 ITALY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 318 ITALY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 319 ITALY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 320 RUSSIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 321 RUSSIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 322 RUSSIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • TABLE 323 RUSSIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2022–2029 (USD MILLION)
  • TABLE 324 RUSSIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 325 RUSSIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 326 RUSSIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 327 RUSSIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 328 RUSSIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 329 SPAIN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 330 SPAIN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 331 SPAIN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • TABLE 332 SPAIN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2022–2029 (USD MILLION)
  • TABLE 333 SPAIN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 334 SPAIN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 335 SPAIN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 336 SPAIN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 337 SPAIN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 338 REST OF EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 339 REST OF EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 340 REST OF EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • TABLE 341 REST OF EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2022–2029 (USD MILLION)
  • TABLE 342 REST OF EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 343 REST OF EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 344 REST OF EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 345 REST OF EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 346 REST OF EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 347 MACROECONOMIC INDICATORS FOR ASIA PACIFIC
  • TABLE 348 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 349 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 350 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 351 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • TABLE 352 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2022–2029 (USD MILLION)
  • TABLE 353 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 354 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 355 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 356 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 357 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 358 CHINA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 359 CHINA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 360 CHINA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • TABLE 361 CHINA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2022–2029 (USD MILLION)
  • TABLE 362 CHINA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 363 CHINA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 364 CHINA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 365 CHINA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 366 CHINA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 367 JAPAN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 368 JAPAN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 369 JAPAN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • TABLE 370 JAPAN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2022–2029 (USD MILLION)
  • TABLE 371 JAPAN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 372 JAPAN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 373 JAPAN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 374 JAPAN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 375 JAPAN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 376 INDIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 377 INDIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 378 INDIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • TABLE 379 INDIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2022–2029 (USD MILLION)
  • TABLE 380 INDIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 381 INDIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 382 INDIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 383 INDIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 384 INDIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 385 AUSTRALIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 386 AUSTRALIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 387 AUSTRALIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • TABLE 388 AUSTRALIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2022–2029 (USD MILLION)
  • TABLE 389 AUSTRALIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 390 AUSTRALIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 391 AUSTRALIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 392 AUSTRALIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 393 AUSTRALIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 394 REST OF ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 395 REST OF ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 396 REST OF ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • TABLE 397 REST OF ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2022–2029 (USD MILLION)
  • TABLE 398 REST OF ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 399 REST OF ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 400 REST OF ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 401 REST OF ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 402 REST OF ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 403 MACROECONOMIC INDICATORS FOR LATIN AMERICA
  • TABLE 404 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 405 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 406 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 407 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • TABLE 408 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2022–2029 (USD MILLION)
  • TABLE 409 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 410 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 411 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 412 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 413 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 414 BRAZIL: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 415 BRAZIL: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 416 BRAZIL: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • TABLE 417 BRAZIL: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2022–2029 (USD MILLION)
  • TABLE 418 BRAZIL: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 419 BRAZIL: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 420 BRAZIL: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 421 BRAZIL: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 422 BRAZIL: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 423 MEXICO: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 424 MEXICO: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 425 MEXICO: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • TABLE 426 MEXICO: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2022–2029 (USD MILLION)
  • TABLE 427 MEXICO: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 428 MEXICO: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 429 MEXICO: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 430 MEXICO: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 431 MEXICO: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 432 REST OF LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 433 REST OF LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 434 REST OF LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • TABLE 435 REST OF LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2022–2029 (USD MILLION)
  • TABLE 436 REST OF LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 437 REST OF LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 438 REST OF LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 439 REST OF LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 440 REST OF LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 441 MIDDLE EAST & AFRICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 442 MIDDLE EAST & AFRICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 443 MIDDLE EAST & AFRICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • TABLE 444 MIDDLE EAST & AFRICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2022–2029 (USD MILLION)
  • TABLE 445 MIDDLE EAST & AFRICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 446 MIDDLE EAST & AFRICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 447 MIDDLE EAST & AFRICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 448 MIDDLE EAST & AFRICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 449 MIDDLE EAST & AFRICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 450 MACROECONOMIC INDICATORS FOR MIDDLE EAST & AFRICA
  • TABLE 451 GCC COUNTRIES: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 452 GCC COUNTRIES: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 453 GCC COUNTRIES: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2022–2029 (USD MILLION)
  • TABLE 454 GCC COUNTRIES: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2022–2029 (USD MILLION)
  • TABLE 455 GCC COUNTRIES: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 456 GCC COUNTRIES: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 457 GCC COUNTRIES: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 458 GCC COUNTRIES: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 459 GCC COUNTRIES: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 460 MACROECONOMIC INDICATORS FOR GCC COUNTRIES
  • TABLE 461 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN MOLECULAR INFECTIOUS DISEASE TESTING MARKET, JANUARY 2021–DECEMBER 2024
  • TABLE 462 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: DEGREE OF COMPETITION
  • TABLE 463 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: REGION FOOTPRINT
  • TABLE 464 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: PRODUCT & SERVICE FOOTPRINT
  • TABLE 465 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: TEST TYPE FOOTPRINT
  • TABLE 466 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: DISEASE FOOTPRINT
  • TABLE 467 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 468 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (1/2)
  • TABLE 469 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (2/2)
  • TABLE 470 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–DECEMBER 2024
  • TABLE 471 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: DEALS, JANUARY 2021–DECEMBER 2024
  • TABLE 472 DANAHER: COMPANY OVERVIEW
  • TABLE 473 DANAHER: PRODUCTS OFFERED
  • TABLE 474 DANAHER: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–DECEMBER 2024
  • TABLE 475 DANAHER: DEALS, JANUARY 2021–DECEMBER 2024
  • TABLE 476 DANAHER: EXPANSIONS, JANUARY 2021–DECEMBER 2024
  • TABLE 477 F. HOFFMANN-LA ROCHE LTD: COMPANY OVERVIEW
  • TABLE 478 F. HOFFMANN-LA ROCHE LTD: PRODUCTS OFFERED
  • TABLE 479 F. HOFFMANN-LA ROCHE LTD: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–DECEMBER 2024
  • TABLE 480 F. HOFFMANN-LA ROCHE LTD: DEALS, JANUARY 2021–DECEMBER 2024
  • TABLE 481 F. HOFFMANN-LA ROCHE LTD: EXPANSIONS, JANUARY 2021–DECEMBER 2024
  • TABLE 482 BIOMÉRIEUX: COMPANY OVERVIEW
  • TABLE 483 BIOMÉRIEUX: PRODUCTS OFFERED
  • TABLE 484 BIOMÉRIEUX: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–DECEMBER 2024
  • TABLE 485 BIOMÉRIEUX: DEALS, JANUARY 2021–DECEMBER 2024
  • TABLE 486 HOLOGIC, INC.: COMPANY OVERVIEW
  • TABLE 487 HOLOGIC, INC.: PRODUCTS OFFERED
  • TABLE 488 HOLOGIC, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–DECEMBER 2024
  • TABLE 489 HOLOGIC, INC.: DEALS, JANUARY 2021–DECEMBER 2024
  • TABLE 490 ABBOTT: COMPANY OVERVIEW
  • TABLE 491 ABBOTT: PRODUCTS OFFERED
  • TABLE 492 ABBOTT: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–DECEMBER 2024
  • TABLE 493 ABBOTT: DEALS, JANUARY 2021–DECEMBER 2024
  • TABLE 494 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
  • TABLE 495 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED
  • TABLE 496 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–DECEMBER 2024
  • TABLE 497 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021–DECEMBER 2024
  • TABLE 498 QIAGEN: COMPANY OVERVIEW
  • TABLE 499 QIAGEN: PRODUCTS OFFERED
  • TABLE 500 QIAGEN: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–DECEMBER 2024
  • TABLE 501 QIAGEN: DEALS, JANUARY 2021–DECEMBER 2024
  • TABLE 502 QIAGEN: EXPANSIONS, JANUARY 2021–DECEMBER 2024
  • TABLE 503 REVVITY: COMPANY OVERVIEW
  • TABLE 504 REVVITY: PRODUCTS OFFERED
  • TABLE 505 GRIFOLS, S.A.: COMPANY OVERVIEW
  • TABLE 506 GRIFOLS, S.A.: PRODUCTS OFFERED
  • TABLE 507 GRIFOLS, S.A.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–DECEMBER 2024
  • TABLE 508 GRIFOLS, S.A.: DEALS, JANUARY 2021–DECEMBER 2024
  • TABLE 509 SEEGENE INC.: COMPANY OVERVIEW
  • TABLE 510 SEEGENE INC.: PRODUCTS OFFERED
  • TABLE 511 SEEGENE INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–DECEMBER 2024
  • TABLE 512 SEEGENE INC.: DEALS, JANUARY 2021–DECEMBER 2024
  • TABLE 513 SEEGENE INC.: EXPANSIONS, JANUARY 2021–DECEMBER 2024
  • TABLE 514 DIASORIN S.P.A.: COMPANY OVERVIEW
  • TABLE 515 DIASORIN S.P.A.: PRODUCTS OFFERED
  • TABLE 516 DIASORIN S.P.A.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–DECEMBER 2024
  • TABLE 517 DIASORIN S.P.A.: DEALS, JANUARY 2021–DECEMBER 2024
  • TABLE 518 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
  • TABLE 519 SIEMENS HEALTHINEERS AG: PRODUCTS OFFERED
  • TABLE 520 SIEMENS HEALTHINEERS AG: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–DECEMBER 2024
  • TABLE 521 SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2021–DECEMBER 2024
  • TABLE 522 SIEMENS HEALTHINEERS AG: EXPANSIONS, JANUARY 2021–DECEMBER 2024
  • TABLE 523 BD: COMPANY OVERVIEW
  • TABLE 524 BD: PRODUCTS OFFERED
  • TABLE 525 BD: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021–DECEMBER 2024
  • TABLE 526 BD: DEALS, JANUARY 2021–DECEMBER 2024
  • TABLE 527 BD: EXPANSIONS, JANUARY 2021–DECEMBER 2024
  • TABLE 528 QUIDELORTHO CORPORATION: COMPANY OVERVIEW
  • TABLE 529 BRUKER: COMPANY OVERVIEW
  • TABLE 530 GENETIC SIGNATURES: COMPANY OVERVIEW
  • TABLE 531 CO-DIAGNOSTICS, INC.: COMPANY OVERVIEW
  • TABLE 532 VELA DIAGNOSTICS: COMPANY OVERVIEW
  • TABLE 533 MOLBIO DIAGNOSTICS PVT. LTD.: COMPANY OVERVIEW
  • TABLE 534 SAVYON DIAGNOSTICS: COMPANY OVERVIEW
  • TABLE 535 UNIOGEN OY: COMPANY OVERVIEW
  • TABLE 536 GENEOMBIO TECHNOLOGIES: COMPANY OVERVIEW
  • TABLE 537 ADVANCED MOLECULAR DIAGNOSTICS: COMPANY OVERVIEW
  • TABLE 538 ALTONA DIAGNOSTICS: COMPANY OVERVIEW
  • TABLE 539 GENEFIRST LIMITED: COMPANY OVERVIEW
LIST OF FIGURES
 
  • FIGURE 1 MOLECULAR INFECTIOUS DISEASE TESTING MARKET SEGMENTATION AND REGIONS COVERED
  • FIGURE 2 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: RESEARCH DESIGN
  • FIGURE 3 KEY INDUSTRY INSIGHTS
  • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS
  • FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 6 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
  • FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
  • FIGURE 8 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: TOP-DOWN APPROACH
  • FIGURE 9 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: DATA TRIANGULATION
  • FIGURE 10 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: PARAMETRIC ASSUMPTIONS
  • FIGURE 11 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024 VS. 2029 (USD MILLION)
  • FIGURE 12 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION)
  • FIGURE 13 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024 VS. 2029 (USD MILLION)
  • FIGURE 14 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024 VS. 2029 (USD MILLION)
  • FIGURE 15 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024 VS. 2029 (USD MILLION)
  • FIGURE 16 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
  • FIGURE 17 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY REGION, 2024 VS. 2029 (USD MILLION)
  • FIGURE 18 RISING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET
  • FIGURE 19 REAGENTS & KITS SEGMENT TO DOMINATE MARKET IN 2029
  • FIGURE 20 MULTIPLEX TESTING SEGMENT TO HAVE LARGEST MARKET SHARE IN 2029
  • FIGURE 21 LABORATORY TESTS TO HOLD LARGEST MARKET SHARE IN 2029
  • FIGURE 22 SEXUALLY TRANSMITTED DISEASES SEGMENT TO LEAD MARKET IN 2029
  • FIGURE 23 POLYMERASE CHAIN REACTION SEGMENT TO HAVE LARGEST MARKET SHARE IN 2029
  • FIGURE 24 DIAGNOSTIC LABORATORIES SEGMENT TO COMMAND LARGEST MARKET SHARE IN 2029
  • FIGURE 25 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
  • FIGURE 26 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 27 NEW REVENUE POCKETS FOR PLAYERS IN MOLECULAR INFECTIOUS DISEASE TESTING MARKET
  • FIGURE 28 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 29 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 30 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 31 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: INVESTMENT AND FUNDING SCENARIO, 2021–2024
  • FIGURE 32 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: PATENT ANALYSIS, JANUARY 2014–DECEMBER 2023
  • FIGURE 33 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: PORTER’S FIVE FORCES ANALYSIS
  • FIGURE 34 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE
  • FIGURE 35 KEY BUYING CRITERIA, BY PRODUCT & SERVICE
  • FIGURE 36 MARKET POTENTIAL OF AI IN MOLECULAR INFECTIOUS DISEASE TESTING APPLICATIONS
  • FIGURE 37 REGIONAL INCIDENCE OF HIV, 2023
  • FIGURE 38 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET SNAPSHOT
  • FIGURE 39 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET SNAPSHOT
  • FIGURE 40 REVENUE ANALYSIS OF KEY PLAYERS IN MOLECULAR INFECTIOUS DISEASE TESTING MARKET, 2021–2023
  • FIGURE 41 MARKET SHARE ANALYSIS OF KEY PLAYERS IN MOLECULAR INFECTIOUS DISEASE TESTING MARKET, 2023
  • FIGURE 42 MARKET SHARE ANALYSIS OF KEY PLAYERS IN EMEA REGION IN MOLECULAR INFECTIOUS DISEASE TESTING MARKET, 2023
  • FIGURE 43 EV/EBITDA OF KEY VENDORS, 2024
  • FIGURE 44 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS, 2024
  • FIGURE 45 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: BRAND/PRODUCT COMPARISON
  • FIGURE 46 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
  • FIGURE 47 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: COMPANY FOOTPRINT
  • FIGURE 48 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
  • FIGURE 49 DANAHER: COMPANY SNAPSHOT (2023)
  • FIGURE 50 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2023)
  • FIGURE 51 BIOMÉRIEUX: COMPANY SNAPSHOT (2023)
  • FIGURE 52 HOLOGIC, INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 53 ABBOTT: COMPANY SNAPSHOT (2023)
  • FIGURE 54 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 55 QIAGEN: COMPANY SNAPSHOT (2023)
  • FIGURE 56 REVVITY: COMPANY SNAPSHOT (2023)
  • FIGURE 57 GRIFOLS, S.A.: COMPANY SNAPSHOT (2023)
  • FIGURE 58 SEEGENE INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 59 DIASORIN S.P.A.: COMPANY SNAPSHOT (2023)
  • FIGURE 60 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2024)
  • FIGURE 61 BD: COMPANY SNAPSHOT (2024)

The study involved major activities in estimating the current market size for the molecular infectious disease testing market. Exhaustive secondary research was done to collect information on the molecular infectious disease testing industry. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the molecular infectious disease testing market.

The four steps involved in estimating the market size are

Secondary Research

In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information as well as assess prospects.

The following is a breakdown of the primary respondents:

Molecular Infectious Disease Testing Market

Note 1: Others include sales managers, marketing managers, and product managers.

Note 2: Companies are classified into tiers based on their total revenues. As of 2023, Tier 1 = >USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = < USD 10 million.

To know about the assumptions considered for the study, download the pdf brochure

COMPANY NAME DESIGNATION
Abbott Regional Sales Manager
F. Hoffmann-La Roche Ltd Product Manager

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the molecular infectious disease testing market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry have been identified through extensive secondary research
  • The revenues generated by leading players operating in the molecular infectious disease testing market have been determined through primary and secondary research.
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

The research methodology used to estimate the market size includes the following:

Molecular Infectious Disease Testing Market

Data Triangulation

After arriving at the overall market size by applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

Molecular infectious disease testing can be defined as molecular techniques used by healthcare professionals to detect and diagnose disease-causing pathogens in human samples such as serum, blood, urine, throat swabs, and stool, among others. Molecular diagnostics is a technique used to identify and analyze nucleic acids or proteins at a molecular level. This technique assesses the genetic makeup of an individual to identify a predisposition to any particular disease or condition and diagnose it.

Stakeholders

  • Senior Management
  • End User
  • Finance/Procurement Department  
  • R&D Department

Report Objectives

  • To define, describe, segment, and forecast the global molecular infectious disease testing market, by product & service, type, test type, disease, technology, and end user
  • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze the micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall molecular infectious disease testing market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the market segments with respect to six regions, namely, North America, Europe, the Asia Pacific, Latin America, Middle East & Africa, and GCC countries
  • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
  • To track and analyze company developments such as product launches & approvals, partnerships, acquisitions, agreements, and other developments
  • To benchmark players within the market using the proprietary Competitive Leadership Mapping framework, which analyzes market players on various parameters within the broad categories of business and product excellence

Previous Versions of this Report

"Our USP is "providing game-changing business opportunities reports with free customization" - so please feel free to provide us with your specific areas of interest / business challenges in much greater detail !!"

We appreciate your interest in this report. Once you fill out the form, you'll be immediately directed to an exclusive solution tailored to your needs. This high-value offering can help boost your revenue by 30% - a must-see opportunity for anyone looking to maximize growth.


By clicking the "Submit" button, you are agreeing to the Terms of Use and Privacy Policy.

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

Growth opportunities and latent adjacency in Molecular Infectious Disease Testing Market

DMCA.com Protection Status